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Abstract:  
This review discusses the progress of India from being one of the largest producers of generics to 
its coming of age and initiating novel drug development programs such as the Open Source Drug 
Discovery for tuberculosis. A few groups have also begun to emerge which focus their research 
on rational or structure based drug design.  We discuss here some of the ongoing efforts in drug 
discovery in India primarily in national research institutions and academia.  
 
* Correspondences to be addressed to:  
skb@igib.res.in  
 
Biotechnology Journal 2009. 4, 348-360 
Drug discovery is an innovative process 
of finding new cures for a particular diseased 
condition.  It can broadly be classified into two 
major categories: non-target based empirical 
drug discovery and target-based rational drug 
discovery. The empirical or classical drug 
discovery approach has largely been dependent 
on serendipity and relies on physiological 
readouts of phenotypes and amelioration of 
disease in a particular assay system.  For 
instance, historical discovery of penicillin to 
discovery of modern day Viagra have been the 
result of good fortune.  A rational target-based 
drug discovery approach, on the other hand, 
begins with identification of a possible target 
with a putative role in a medical condition.  
Technological advances in the field of genomics, 
proteomics and computational tools have been 
the main driver of target-based drug discovery 
over the last few decades. A few drugs 
developed by this approach worldwide are 
captopril (an inhibitor of angiotensin converting 
enzyme and used for hypertension), 
dorzolamide, (a carbonic anhydrase inhibitor for 
glaucoma), saquinavir (protease inhibitor for 
treatment of AIDS) and zanamivir 
(neuraminidase inhibitor against influenza).  
Explosion of genome wide information of 
various organisms due to improvements in 
sequencing technologies has led to a large 
repertoire of identifiable drug targets. However, 
dissecting “druggable” targets from the potential 
ones is still a big challenge (Hopkins and 
Groom, 2002; Russ and Lampel, 2005). These 
drug targets may be proteins or nucleic acids 
involved in regulation, signaling or different 
metabolic conditions. Key enzymes in 
biochemical and regulatory pathways, as well as 
virulence factors of infectious organisms act as 
potential drug targets. Biochemical and 
structural knowledge of the target helps 
understand the mechanism of action of the 
disease and in the design of specific 
compounds to hit the target.  Although several 
groups are involved in collaborative and 
complementary approaches to identify drug 
targets and their three-dimensional structure 
determination to aid drug design, rational target 
based drug design in India still awaits major 
conceptual breakthroughs.  One of the major 
focus areas of India’s efforts in drug discovery 
over the years has been the development of cost 
effective and innovative processes for generic 
drugs. Domestic pharmaceutical companies have 
traditionally thrived on innovating process 
patents and by using low labor and research 
costs to export generic drugs to developed-
country markets, including the US. Drug prices 
in India are hence much lower than the prices of 
similar drugs in several countries including the 
United States, United Kingdom as well as 
Pakistan and Indonesia (Agarwal, SP et al., 
2007). Today, India has the largest number of 
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FDA approved manufacturing facilities in any 
country outside the United States. Several low 
cost and commercially viable technologies for a 
wide range of essential drugs, such as anti-
cancer, anti-virals, anti-bacterials, anti-
glaucoma, anti-inflammatory, analgesics, and 
cardio-vascular drugs, among others have been 
developed.  An important contribution of Indian 
generics industry has been in bringing down the 
cost of antiretroviral therapy for HIV/AIDS 
treatment by the efforts of Indian Institute of 
Chemical Technology (IICT), Council of 
Scientific and Industrial Research (CSIR) and 
Indian pharmaceutical companies like CIPLA, 
which has made drugs available to more than 
250,000 HIV patients in poor countries at very 
cheap rates. India has been a major exporter of 
relatively cheap Active Pharmaceutical 
Ingredients (APIs) and pharmaceutical 
formulations of several medicines, notably 
vaccines and antiretrovirals (ARVs).  
 
GENERICS IN INDIA: A HISTORICAL 
PERSPECTIVE  
A number of research institutes in India are 
involved in the development of new 
technologies and process formulations for the 
production of generics. These technologies have 
enabled the Indian drug industry to emerge as 
one of the largest producers of generic drugs in 
the world. India has an estimated 24,000 drug 
manufacturers (DOCP Annual Report (2007-
2008). Together they produce output valued at 
nearly US $18 billion, accounting for nearly 1 
percent of our GDP. Indian pharma industry 
stands today 4th (8%) in terms of volume and 
13th in terms of value of production having 
nearly 22% of the global generic market 
(http://www.indiainbusiness.nic.in/industry-
infrastructure/industrial-sectors/drug-
pharma.htm,). Besides exporting pharmaceutical 
products to a large number of developed 
countries like US, UK, Germany, Russia and 
Japan, India is also a low-cost supplier of 
generic drugs to several less-developed 
countries, like Nigeria, Vietnam, Sri Lanka, 
Pakistan, Bangladesh and Nepal. However, in 
spite of our tremendous growth in production of 
generics and new process formulations, share of 
India’s pharmaceutical industry in the world 
market is a mere 1.3% of a global sale of nearly 
US $785 billion. The scenario is expected to 
improve as leading industries acquire skills and 
confidence to engage in high-end, new drug 
discovery research and technology development.  
The Indian Patent Act of 1970 replaced the 
Indian Patents and Designs Act of 1911 and 
brought in major changes. The Patents Act of 
1970, which was implemented in 1972, did not 
allow product patents on foods, pharmaceuticals 
and chemicals but allowed only process patents 
in these categories. The outdated Act of 1911 
had previously allowed patenting of 
pharmaceutical products, resulting in very high 
price of medicines as controlled by MNCs. The 
changes in the 1970 Patents Act gave an impetus 
to formulation of new process technologies and 
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reverse engineering methods for manufacture of 
various essential medicines and ensured that 
these could be available to people at affordable 
prices (Thomas, 2006). Other changes brought 
in the Act included reduction in the time period 
for patents from 16 years to five years (from the 
date of patent granting or seven years from the 
date of patent application) and mandatory 
domestic manufacturing within three years from 
the date of sealing of the patent. In addition, a 
Drug Price Control Order (1970) was also 
introduced to control the maximum price that 
could be charged for any drug.  
The government support in the area of 
healthcare had begun with the set up of drug 
manufacturing companies in the public sector, 
Hindustan Antibiotics Limited (HAL) (1954) 
and Indian Drugs and Pharmaceuticals Limited 
(IDPL) (1961). The production of modern 
medicines in India, however, dates back to more 
than a century.  Pharmaceutical companies with 
a long history in India include Bengal Chemicals 
& Pharmaceuticals Limited (BCPL), established 
in 1901, Alembic Chemical Works (1907) 
Bengal Immunity Ltd. (BIL) (1919), and Smith 
Stanistreet Pharmaceuticals Ltd (SSPL). Many 
of these pharmaceuticals were nationalized and 
some are involved in the production of 
pharmaceutical products, major bulk drugs and 
chemicals using indigenous technologies even 
today. In addition, there are a number of 
pharmaceutical manufacturing units under the 
control of state governments, such as Goa 
Antibiotics Ltd., Karnataka Antibiotics and 
Pharmaceuticals Ltd., Rajasthan Drugs and 
Pharmaceuticals Ltd etc (Maggon, 2003). 
National R&D institutions were set up by CSIR, 
namely,; National Chemical Laboratory in Pune 
in 1950, Central Drug Research Institute in 
Lucknow in 1951 and Indian Institute of 
Chemical Technology (IICT), formerly known 
as Regional Research Laboratory (RRL), in 
Hyderabad in 1956, all of which have a wealth 
of scientific knowledge and are staffed by highly 
qualified scientists. Over the years, NCL, CDRI 
and IICT have developed many process 
technologies for various drugs and these have 
been widely used by many top as well as small-
scale pharmaceutical companies in India.  
NCL has been developing many significant 
technologies for use in manufacture of various 
drugs. The organic synthesis group at NCL has 
developed cost-effective processes for anti HIV-
agents viz., AZT, stamuvidine, lamuvidine, 
cardiac and antimalarial drugs etc. Among 
successful technologies developed by NCL 
include manufacture of epibatidine, a painkiller 
with potency 200 times higher than morphine 
and a new process using zeolite catalyst for the 
manufacture of ranitidine, an anti-ulcerant and 
one of the world’s largest selling drug. Alternate 
and cost-efficient process technologies have also 
been developed for including etoposide, 
atorvastatin, irinotecan, neverapine, ziprasidone, 
cisapride, celiprolol and many other important 
drugs. A new process for Biotin, one of the B-
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complex group of vitamins has also been 
developed.  NCL is also exploring synthesis and 
purification methodologies for chiral molecules 
as drugs. Some important industrial partners 
where technologies have been transferred for 
manufacture and marketing include Alembic, 
Cadilla, CIPLA, Dabur, Emcure, Glenmark, 
Godrej Agrovet, Lupin, Orchid Chemicals, 
Ranbaxy, RPG Life Sciences etc. 
CDRI has helped develop over 100 technologies 
for bulk drugs, drug intermediates, and 
biological / fermentation products. Apart from 
successes in new drug or technology 
development, CDRI has also been involved in 
development of many generics marketed by 
leading pharmaceuticals companies viz., 
acyclovir (Ranbaxy), ephedrine hydrochloride 
(Malladi Drugs & Pharmaceuticals), 
dextropropoxyphene hydrochloride 
(Wockhardt), pyrithioxin (Themis Chemicals), 
clofazimine (Astra-IDL), 5,6-dimethyl-
benzimidazole (K. Methaqualone & Chemicals), 
N-methyl piperazine, artemether (IPCA Labs). 
Today, CDRI’s technology partners is a long list 
of industries which includes CIPLA, Dabur, 
Hindustan Latex, Lupin, Nicholas Piramal, 
Torrent, Unichem and many others.  
IICT has played a major role in drug 
development and placing India in the global 
generic map. Among major drug development 
approaches, IICT has developed an innovative 
and cost-effective approach to AZT and 
subsequently to other HIV-inhibitors such as 
betzalladines, calanolides, mischellamines and 
HIV protease inhibitors. They also developed 
technologies for many other drugs like 
diazepam; salbutamol; anti-cancer drugs viz., 
vinblastine, vincristine, etoposide; anti-diabetic 
drug tolbutamide; anti-inflammatory drugs 
enfenamic acid, flurbiprofen; enalapril for high 
blood pressure and antibacterial agents viz., 
sultamicillin, azithromycin, norfloxacin and 
ciprofloxacin. In addition, process for 
pentamidine for the cure of Kala azar (visceral 
leishmaniasis) was also developed at IICT and 
transferred to CIPLA. IICT has also developed 
docetaxel, Taxol C-13 side chain (API 
intermediate) and several new anti-cancer 
agents.  Among other technological 
achievements, IICT is also making efforts 
towards development of technology for cost-
effective synthesis of pure chiral compounds. 
Timolol maleate, an anti glaucoma agent was the 
first chiral drug successfully developed at IICT 
in 1989 and transferred to FDC Ltd.   IICT has a 
long list of technology partners which includes 
Armour Chemicals, Bombay Drug House, 
Cadilla, Cheminor Drugs, CIPLA Coromandal 
Pharma, Dabur, IDPL, Indus Pharma, Lupin, 
Nicholas Piramal, Ranbaxy, Reddy’s 
Laboratories, Sun Pharmaceuticals, Torrent 
Pharmaceuticals, Unichem, Zydus and many 
others. 
Powered by its achievements in developing 
novel reverse engineering methods, India is 
today a world leader in the generics market 
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worldwide. Over 100 major drugs and more than 
300 bulk drugs are produced in India using 
totally indigenous cost-effective technologies. 
The previous patents regime facilitated the 
development of the Indian generics industry by 
encouraging reengineering of existing high-
priced drugs by alternate processes. Along with 
several “path-breaking” technologies developed 
by national R&D institutions and transferred to 
pharmaceutical companies for use in large scale 
development, research at leading pharma centres 
also enhanced capabilities in reverse engineering 
methods for large scale production of 
pharmaceutical products. Under its WTO 
commitments, however, India has changed its 
patent regime to allow patenting rights to both 
products as well as processes. Indian drug 
companies can no longer sell drugs patented by 
other firms unless they are licensed to do so. 
Driven by the change to a product patent regime 
and the opportunities offered in the international 
market, the mindset of R&D in India is shifting 
towards innovative research. While the initial 
focus of most of the national R&D institutions 
was development of reverse engineering 
capabilities for generics, there is a concerted 
effort towards discovery and development of 
newer therapies, many of which are in later 
stages of development or clinical trials. 
EARLIER AND PRESENT PHASE OF 
DRUG DISCOVERY IN INDIA 
The discovery of urea stibamine and its effective 
use for the treatment of kala azar in the 1920s by 
Prof. U.N. Brahmachari marked one of the first 
major success stories of modern drug 
development in India. India has since come a 
long way with several groups of scientists in 
national R&D institutions and in academia 
developing cost-effective drugs and technologies 
for various ailments affecting the local 
population. 
Centchroman, a non-steroidal oral contraceptive 
for women was developed by CDRI in the 
1980s. Centchroman acts by modulating the 
balance between estrogen and progesterone at 
the uterine level without interfering with their 
synthesis or blood levels and was the first anti-
implantation agent approved for clinical use in 
the world. Centchroman offers a combination of 
weak estrogenic and antiestrogenic properties 
that inhibits the fertilized ovum from nidation 
and thus prevents pregnancy. Since it does not 
disturb the endocrine system, it is considered 
much safer than other steroidal alternatives. 
Centchroman is a popular contraceptive for 
women and has been in the market in India for 
many years under its trade name ‘Saheli’.  
α,β-Arteether, a semi synthetic derivative of 
artemisinine, developed at CDRI in 
collaboration with Central Institute of Medicinal 
and Aromatic plants (CIMAP), Lucknow is 
useful as a second line of treatment for 
chloroquine-resistant P. falciparum malaria 
including cerebral malaria. The drug has been 
licensed to Themis Chemicals Ltd., Mumbai and 
is being marketed as an injectable formulation, 
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under the trade name ‘E-Mal’.  Post marketing 
surveillance data of Arteether has indicated no 
drug related side effects so far.  Another anti-
malarial that has undergone extensive trials and 
is currently being marketed is the priamquine 
derivative bulaquin.  Bulaquin is used in 
combination with chloroquine as anti-relapse, 
antimalarial for prophylactic against P. vivax 
malaria and does not have the 
methaemoglobinaemia or leukopenia side effects 
caused by primaquine.  
Taking a lead from ancient Indian system of 
medicine of Ayurveda, scientists at CDRI 
identified gugulsterones from the extracts of 
plant Commiphora mukul (commonly known as 
"Gugglu") for its cholesterol lowering 
properties. The fraction containing active 
constituents is currently marketed as ‘gugulip’ 
by CIPLA. A synthetic substitute for gugulip 
that acts through FXR nuclear receptor to inhibit 
bile acid mobilization in liver has now been 
developed and is currently under Phase III 
clinical trials. Another molecule, Picroliv, a 
hepatoprotective agent of plant origin has been 
developed. Picroliv has antiviral and 
immunostimulant activities. It is devoid of any 
significant Central Nervous System (CNS), 
cardiovascular system (CVS), autonomic and 
other systemic activity. Phase III clinical trials 
are in progress in patients of tuberculosis 
receiving multi drug therapy and in patients 
suffering from alcoholic cirrhosis. 
In addition, several R&D programmes, viz., the 
Drug and Pharma Research Programme (DPRP) 
of Department of Science and Technology 
(DST) have been initiated to boost innovative 
research in the area of drug discovery and 
development in India. DPRP aims to support 
development of new drug formulations and 
create infrastructure to facilitate drug discovery 
in industry as well as academia. At present there 
are 85 industry-institution alliances involving 60 
industries and 38 public funded institutions. This 
program funds 85 research projects at 32 
national R&D institutes and 38 research projects 
to industry. Collaborative efforts in the area of 
drug and vaccine development for various 
diseases like malaria, tuberculosis, 
cardiovascular diseases, hepatitis B, dengue etc 
are being pursued under this programme.  
New Millennium Indian Technology Leadership 
Initiative (NMITLI) program of CSIR also aims 
to boost partnerships between public and 
privately funded R&D institutions. About 57 
projects developed under the NMITLI program 
over the years involving 80 industry partners and 
270 R&D groups from different institutions are 
currently being pursued. Of these, 11 projects 
with a total outlay of nearly Rs. 100 crores (US 
$20 million) are aimed specifically towards drug 
development programmes. Some of the products 
developed under the NMITLI programme have 
been approved as Investigational New Drug 
(IND) and are at different stages of clinical 
studies. 
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No preventive or curative therapy exists for 
psoriasis except the symptomatic management. 
Based on the traditional knowledge and using 
the reverse pharmacology approach, a single 
plant based oral herbal formulation has been 
developed under NMITLI collaborative 
programme which includes Lupin Laboratories 
as the industrial partner and CDRI and NIPER, 
Mohali as the partners from national R&D 
institutes. After extensive safety, efficacy, 
toxicology and pharmacokinetic studies, the 
formulation has been filed as an IND, a first in 
the country for an herbal based formulation. The 
formulation has cleared phase II clinical studies 
and is currently undergoing phase-IIb & III 
studies.  
In a successful collaboration under the NMITLI 
programme, the expertise of 12 institutional 
partners and Lupin Laboratories as the industry 
partner were synergized for the development of 
new targets, drug delivery systems, bio 
enhancers and therapeutics.  A new chemical 
molecule, Sudoterb (LL-3858), has been 
developed for the treatment of tuberculosis. The 
molecule is active alone and also compatible 
with the four-drug combination therapy of 
tuberculosis and works well replacing some of 
the drugs from the standard tuberculosis 
regimen. The molecule is less toxic, clears the 
total infection within two months and no 
recurrence has been observed in animal studies. 
This would be one of the first global successes 
achieved in developing a new therapeutic 
molecule for tuberculosis in more than 40 years. 
An Investigational New Drug (IND) application 
for the molecule has been cleared and clinical 
trials are in progress.  
Another achievement under the NMITLI 
scheme has been the development and 
improvement of lysostaphin as a biotherapeutic 
under collaborative efforts of Institute of 
Genomic and Integrative Biology (IGIB), 
CDRI and Bharat Biotech. Lysostaphin is a 27-
kDa-glycylglycine endopeptidase produced by 
Staphylococcus simulans that kills all other 
strains of Staphylococcus by cleaving the 
penta-glycine bridges linking the 
peptidoglycans in their cell wall. Due to its 
rapid and unique mechanism of action, 
lysostaphin has the potential to substitute 
and/or augment antibiotics as the first line of 
treatment for S. aureus infections. The 
development of lysostaphin as a therapeutic 
agent has had a major limitation over the years 
due to potential immunogenicity of a 
parenterally administered protein and the 
impurity of lysostaphin preparations. Under the 
NMITLI program, the technology for 
recombinant mature lysostaphin was developed 
at IGIB and licensed to the Bharat Biotech to 
obtain lysostaphin that is > 90% pure, free from 
pre-pro and pro-lysostaphin and that can be 
produced in large quantities from E. coli. This 
overcomes all problems of potential 
immunogenicity from impure protein 
therapeutic. The development is protected as a 
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product patent in several countries. The studies 
have shown the drug to be efficacious in 
controlling topical infection caused by drug 
resistant strains of Staphylococcus aureus. 
Elaborate pre-clinical animal studies on 
lysostaphin gel and cream formulations 
indicated no adverse pharmacological and 
toxicity effects. The formulation was the first 
biotech molecule to clear IND in India. 
Presently, the formulation is undergoing Phase 
II clinical trials in patients.  
Furthermore, poly herbal formulations, for 
diabetes, arthritis and hepatocellular protection, 
have been developed under the NMITLI 
program based on traditional medicinal system 
and following reverse pharmacology approach 
using modern science and medicine tools. Phase 
III clinical studies have recently been concluded 
on many of these molecules and the results are 
being analyzed.  
Recent research activities towards Drug 
Targets Discovery and Development 
Subsequent to the enthralling success of generics 
as well as some new product development, a 
large number of institutes and individual 
investigators are making remarkable 
achievements today to find specific inhibitors or 
lead compounds against various diseases.  Many 
new candidate drugs and nutraceuticals have 
been developed indigenously. Several institutes 
and groups in the country are focused to new 
product development in the areas of cancer, 
diabetes, osteoporosis, malaria, leishmaniasis, 
tuberculosis etc. ‘Bio-therapeutics’ or use of 
synthetic or naturally occurring biological 
compounds, small molecules and their 
derivatives for therapeutic purposes is also being 
developed.  While it is not possible to elaborate 
on basic research activities of a large number of 
groups actively involved in dissecting the 
molecular and genetic basis of various diseases, 
some of the recent research activities through 
institutional or individual efforts that have led to 
or have a strong potential of being a candidate 
drug molecule are briefly described in this 
section. 
 
Peptides and peptidomimetics have a strong 
potential for use as novel drug therapeutics. 
Synthetic peptides are being studied at the 
Institute of Science (IISc), Bangalore to dissect 
the rules governing formation of secondary 
structure elements in proteins. Several synthetic 
peptides have been constructed using unnatural 
amino acids to introduce local constraints and 
understand peptide folding and stability in 
greater detail. Insights from these studies have 
been used in design of synthetic interface 
peptides, which can potentially impede subunit 
association of triosephosphate isomerase, a 
potential drug target of Plasmodium falciparum 
(Singh et al., 2001). In addition, studies on 
peptides from venom extracts of marine cone 
snails, Conus amadis to explore the potential of 
development of new pharmacophores are being 
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carried out (Sudarslal et al., 2003).  In a separate 
study carried out at CDRI, synthetic peptides for 
use as antifungal agents with high efficacy in 
combination with standard antifungal agents 
have been identified (Kundu et al., 2002).  
Several other groups have now begun to explore 
role of peptides as potential inhibitory 
molecules. Investigators at CCMB are currently 
studying the antibacterial role of synthetic 
human beta-defensin analogs, which exhibit 
activity against Escherichia coli and 
Staphylococcus aureus (Krishnakumari et al., 
2006). The antibacterial activities were 
attenuated in the presence of increasing 
concentrations of NaCl and divalent cations such 
as Ca2+ and Mg2+ with the site of action being 
the bacterial membrane. Since this research has 
important impact in the development of 
antibacterial peptides as therapeutic agents, a US 
patent has been secured.  In another recent 
report, a synthetic peptide derived from the 
leucine zipper motif of hemolysin E of E. coli 
has been shown to inhibit the hemolysin activity 
against human red blood cells (Yadav et al., 
2008).  This peptide has been modified by 
substitution of leucine residues at ‘a’ and/or ‘d’ 
position of the heptad repeat with single or 
double alanine residues, thereby reducing the 
toxicity of Leucine Zipper Peptide (LZP) against 
human red blood cells (hRBCs), as it impaired 
the binding and localization of LZP to hRBCs. 
 
 
Proteins as biopharmaceuticals:  
A significant step in the use of proteins as 
therapeutics has been the successful 
development and marketing of clot-dissolving 
agents viz., streptokinase. IMTECH, Chandigarh 
has successfully developed a cost-effective 
technology for production of therapeutic grade 
streptokinase by biotechnological means and 
transferred the technology to Cadilla for 
production and marketing in India as ‘STPase’. 
IMTECH also developed an engineered clot-
specific streptokinase that becomes active only 
when it encounters the blood clot.  The 
technology was transferred to Nostrum 
Pharmaceuticals for worldwide clinical 
development and marketing. In addition, Bharat 
Biotech and Shantha Biotech have also 
independently developed recombinant 
streptokinase for therapeutic use and are 
currently being marketed as Indikinase and 
Shankinase, respectively. 
The development of lysostaphin as a therapeutic 
agent against Staphylococcus infections has 
already been described.  Another protein with 
important therapeutic role, recombinant 
epidermal growth factor is being successfully 
used for treatment of for Diabetic Foot Ulcers as 
well as for burns and skin grafts.  This 
recombinant protein was developed at IGIB and 
is being marketed by Bharat Biotech as 
‘REGEN-D’. In other significant achievements, 
several groups from different institutes have 
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identified various protein molecules as 
biomarkers which may help in the early 
diagnosis of various types of cancer.   
Natural compounds: In recent leads, some 
natural products (dihydrobetulinic acid, luteolin, 
diospyrin and indolyl quinolines) were identified 
as inhibitors of leishmanial topoisomerases at 
IICB.  In addition, researchers at IICB found 
herbal formulations obtained from M. koenigii 
and Tribulus terrestris to be useful for the 
treatment of prostate cancer and is currently 
being marketed under the brand name 
‘Prostalyn’. Another molecule isolated from the 
flowers of Woodfordia fruticosa at IICB has 
been found to be useful against peptic ulcers. A 
patent application has been filed in several 
countries. 
In a collaborative effort from scientists at 
National Centre for Cell Sciences (NCCS), 
National Institute of Oceanography (NIO) and 
International Centre for Genetic Engineering and 
Biotechnology (ICGEB), two anti-malarial 
compounds from mussels, ‘NIO-1’ and ‘NIO-2’ 
have been found to have very specific activity 
against Plasmodium falciparum. The license to 
commercialize the drug process has already been 
transferred to a Mumbai-based company Shreya 
Life Sciences. 
TOWARDS RATIONAL DRUG DESIGN  
Worldwide, several groups are making inroads 
into tackling various diseases by development of 
novel inhibitors or lead molecules through 
rational drug design efforts. This involves 
computer-aided drug design methods including 
structure based drug design (SBDD), ligand-
based drug design, de novo synthesis for the 
drug targets identification etc. In India, a major 
effort of majority groups in rational drug design 
is focused towards identification and discovery 
of potential targets for further use in drug 
development processes. Many companies have 
initiated work towards creating integrated in-
silico drug design tools, molecular docking and 
virtual high throughput screening to help reduce 
the discovery time. There are large number of 
Contract Research Organizations (CROs) in 
India which are getting involved in various 
stages of drug discovery giving a significant 
thrust to the pharma companies to achieve their 
goals (Clark and Newton, 2004). Many of these 
companies have also been recognized by 
Department of Scientific and Industrial Research 
as premier R & D centres.  Some of the CROs 
based in India and their specializations are 
summarized in Table 1. Although not an 
exhaustive list, the table provides an overview of 
various stages of drug development that are 
being aided by an increasing number of CROs 
and expertise of talented researchers available 
therein. 
Computational efforts:  
A major collaborative effort for drug target 
identification and drug development using 
computational approaches has been initiated as a 
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collaborative project among several CSIR labs.  
This project aims to develop new software and 
strategies to enable identification of therapeutic 
targets; to design and develop new tools for 
predicting toxicity and drug response in-silico; 
and to generate qualified and trained IT 
professionals for pursuing research in the area of 
bioinformatics.  As ongoing efforts of this 
project, many non-coding DNA structural motifs 
have been validated experimentally as potential 
targets (Verma et al, 2008, Thakur et al, 2008). 
Novel approaches have been developed to 
identify protein targets in infectious organisms. 
One such approach uses the invariant peptide 
approach. Invariant peptides with an 
evolutionary pressure in at least seven organisms 
were identified and found to act either as 
‘functional signatures’ or fold determinants in 
several proteins (Prakash et al., 2004; Prakash et 
al., 2005). Invariant peptide regions of 
functionally important proteins of M. 
tuberculosis are being explored as potential drug 
targets. In another study, unstructured regions in 
essential proteins have been proposed to be 
important functional regions that may be 
targeted for drug development (Debasis Dash, 
personal communication). 
Synthetic small interfering RNAs (siRNAs) 
 siRNAs have found wide applications in 
therapeutics since these can direct the cleavage 
of perfectly complimentary target mRNAs and 
knock down the expression of a gene in a highly 
specific manner. A natural analog of siRNAs, 
microRNAs (miRNAs) down regulate targets 
with incomplete complementarity. miRNAs can 
sequester targets in silenced complexes and may 
be capable of simultaneously shutting down 
many members of a biological pathway and 
hence can be of potential therapeutic use. Role 
of miRNA in host-pathogen interactions and 
their potential use in therapeutics are being 
explored and have been reviewed recently 
(Scaria et al., 2007). Efforts are underway at 
many academic and pharmaceutical research 
organizations in inter-institutional collaborative 
programmes to explore such methodologies in 
the field of drug discovery.  
 
Structure based drug design (SBDD)  
Structural biology forms an integral part of 
rational computer aided drug design methods. 
The main approaches to determine three-
dimensional structures are X-ray crystallography 
and NMR.  Macromolecular crystallography 
took early shape in India primarily through the 
crystallography work on lectins in the initial 
years and has been reviewed recently (Vijayan, 
2007a; 2007b).  Over the years, as many as 20 
research institutions now have macromolecular 
crystallography as one of the major tenets in 
tackling various biological problems. Many of 
these groups target SBDD for identified protein 
targets as a primary objective of their research 
goals.  A number of research groups are 
addressing problems associated with infectious 
diseases relevant to India.  One of the major 
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successes emanating from the relatively new 
field of SBDD efforts in India, however, is on 
phospholipase A2 (PLA2). 
PLA-2 is an enzyme involved in production of 
eicosanoids. It catalyzes the hydrolysis of the sn-
2 ester linkage of glycerophospholipids to 
release fatty acid and lysophospholipid. Any 
imbalance in the physiological concentrations of 
eicosanoids is associated with various diseases 
viz., inflammation, rheumatism, arthritis and 
asthma. Structures of several isoforms of snake 
venom PLA2 (reviewed recently in Singh et al., 
2007) and bovine phospholipases (Sekar et al., 
1997) are available.  Crystal structures of PLA2 
in apo form and in complex with various natural 
compounds viz., anisic acid, atropine, 
aristolochic acid, tocopherol (vitamin E), 
substrate analogs, indole derivatives and several 
NSAIDs, viz., indomethacin and aspirin are 
available. The structure of PLA2 has revealed 
that the substrate binding site consists of a large 
linear hydrophobic channel ending into the 
active site consisting of residues His48, Asp49, 
Tyr52 and Asp99. The binding site can be 
divided into six subsites. Detailed structural 
analysis of different complexes revealed that 
most of the currently available inhibitors bind to 
only a few of these subsites resulting in poor 
potency. The structural analysis of specifically 
designed peptide LAIYS in complex with PLA2 
confirmed that the hydrophobic residues of the 
peptide interact with the hydrophobic channel of 
the binding site and placed the hydroxyl group 
of tyrosine for interaction with Asp49 and His48 
yielding a binding affinity of approx 8.8 x 10-9 
M. Further modification of this peptide to 
FLSYK in order to exploit electrostatic 
interactions between the peptide and active site 
has resulted in a binding affinity of 1.1 x 10-9 M 
for the peptide inhibitor (Chandra et al., 2002). 
The design of this highly specific peptide 
inhibitor is exciting and instills confidence in 
indigenous SBDD efforts towards other protein 
targets in the recent future.  
Apart from the SBDD studies on pain and 
inflammation, a few groups are addressing 
molecular mimicry and antibody maturation (for 
instance, Jain et al., 2001). However, structure 
based drug design in India is largely aimed 
towards pathogenic organisms prevalent in 
tropical countries, particularly India; 
Mycobacterium tuberculosis, Plasmodium 
falciparum, Salmonella typhimurium, E. 
histolytica and L. donovani and HIV to name a 
few. A large number of these efforts have been 
focusing on drug target identification and 
structural characterization that may serve as 
templates for SBDD in subsequent stages. 
Three-dimensional structures of Triose 
phosphate isomerase (Velanker et al., 1997; 
Parthasarthy et al., 2002; Eaazhisai et al., 2004a) 
and adenylosuccinate synthetase (Eaazhisai et 
al., 2004b) of P. falciparum, important drug 
targets, in complex with several ligands and 
substrate analogues have been obtained in order 
to obtain leads into design of therapeutics. Fatty 
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acid biosynthesis and its inhibition by triclosan 
is being investigated in detail to improve the 
specificity of antimalarials (Surolia and Surolia, 
2001; Suguna et al., 2001). In addition, peptide 
derivatives have been designed for inhibition of 
plasmepsins, key enzymes in the life cycle of 
Plasmodium and their inhibitory effects being 
investigated to further aid drug development 
against this pathogen (Kesavulu et al., 
2005). Several potential inhibitory molecules are 
being explored through crystallography 
complexes against HIV protease for design of 
specific inhibitors (Pillai et al., 2004; Das et al., 
2007; Bihani et al., 2008).  Structural efforts into 
protein targets of Leishmania donovani, the 
causative agent of kala azar, S. 
typhimurium and E. histolytica have also been 
initiated and would be important steps in drug 
design against these pathogens.  
Mycobacterium tuberculosis, a major threat in 
India: structural efforts  
The crystal structure of RecA from 
Mycobacterium tuberculosis (Datta et al, 2000), 
a protein involved in homologous DNA 
recombination and repair was one of the first 
structures of a mycobacterial protein from India. 
Over the last decade, several groups have taken 
up the structure determination of proteins from 
this dreaded pathogen, causative agent of largest 
number of deaths by a single infectious 
organism worldwide. At present, India alone 
accounts for nearly 10% of all available crystal 
structures of M. tuberculosis. Structures of many 
important drug targets of M. tuberculosis viz., 
uracil-N-glycosylase (Kaushal et al., 2008), 
Pantothenate kinase (Das et al., 2006), 
chorismate mutase (Qamra et al., 2006), NAD+ 
dependant DNA ligase (Srivastava et al., 2005), 
lysine ε-amino transferase (Tripathi et al., 2006), 
polyketide synthase (Sankaranarayanan et al., 
2004), peptidyl tRNA hydrolase (Selvaraj et al., 
2007; Pulavarti et al., 2008) to name a few have 
been determined in India.  The design of specific 
inhibitors as potent lead molecules for drug 
development is being carried out in several labs.  
One protein target of M. tuberculosis against 
which SBDD has led to identification of specific 
inhibitors with IC50 in low micromolar ranges is 
the NAD+ dependent DNA ligase (Srivastava et 
al., 2005).  NAD+ dependent DNA ligases are 
present in bacteria and certain entomopox and 
mimi viruses.  They are essential for bacterial 
growth and hence considered as important drug 
targets. Glycosyl ureide, glycofuranosylated 
diamines and tetracyclic indole derivatives have 
been identified as novel inhibitor molecules that 
specifically inhibit the M. tuberculosis NAD+ 
dependent ligases over other bacterial ligases.  
Further analysis of its binding pockets and 
interactions with bound water networks is being 
carried out to further improve the inhibitor 
selection. In addition, the group has identified 
that BRCT-domain of DNA ligase is essential 
for the bacterium's survival and is currently 
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carrying out molecular docking studies to 
explore inhibitors against this domain as well. 
 
OPEN SOURCE DRUG DISCOVERY: A 
PARADIGM SHIFT  
The Council of Scientific and Industrial 
Research in India has recently initiated a novel 
comprehensive drug discovery programme 
termed ‘Open Source Drug Discovery for 
Tuberculosis’ (OSDD) (http://www.osdd.net/), a 
network project encompassing R&D institutions, 
academic institutes, Universities and Industries 
in a collaborative mode (refer Commentary by 
Singh, 2008).  This project aims to employ 
modern genomic, proteomic and informatics 
technologies with a strong inclination to apply a 
concerted effort to address the Drug Discovery 
programme against tuberculosis.  The project 
draws strengths from the success of Open 
Source models for IT (e.g., World Wide Web 
Technology, GNU/Linux Operating System) and 
Biotechnology (e.g., Human Genome 
Sequencing). The Government of India has 
committed Rs. 150 crores (US $30 million) 
towards this project. An equivalent amount of 
funding is expected to be raised from 
international agencies and philanthropists. 
Nearly 50 crores (US $10 million) has been 
already released for Phase I of the project.  
Nearly one-third of the world's population is 
presently infected with tuberculosis with India 
being the highest TB burden country 
globally. OSDD provides an open platform to 
"collaborate, share and discover" and also 
provides tools for the same. OSDD contains a 
comprehensive TB database called Mtb Sysborg, 
which provides extensive information related to 
the complex biology of the pathogen, drugs and 
their interaction with different proteins, protein-
protein interactions etc.  It also provides 
computational resources at one unique platform 
to aid the initial stages of target identification 
and drug discovery (http://crdd.osdd.net/).  Open 
bookmarks and TBprints archive are other tools 
to share discussions, online resources as well as 
to provide published and unpublished data 
related to drug development against 
tuberculosis. Current developments in the 
project includes several active sub-proposals to 
identify drug targets, virtual screening and in 
silico toxicity work.  
The OSDD programme has been divided into 
several research packages to address various 
stages of a Drug Discovery process. It aims to 
encourage and support ideas and sub-proposals 
from the scientists at all stages of this process in 
an open source mode. Since a Drug discovery 
program would require expertise from scientists, 
doctors and technocrats from diverse schools of 
thoughts and disciplines, current partners in the 
OSDD program are from diverse research fields 
and cutting across barriers of university, industry 
and institutional structures. This novel way of 
recognition serves as an important platform for 
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multi-partnership in OSDD and enriches the 
OSDD project. The work for drug discovery and 
development is proposed to be shared with 
Academia, University students and CRO’s at 
much lower cost and at a much varied platform.   
These sub-projects with defined short goals can 
hence be implemented at minimal costs and will 
also be a matter of pride and challenge for the 
brilliant young students contributing in various 
stages of the project. 
Protection in OSDD is through clickwrap and 
copyleft protection. Therefore, the processes of 
sharing knowledge and encouragement of 
growth of ideas can go at fast pace. All IPR 
rights will be shared among the OSDD 
community whose contributions are monitored 
by a microattribution system. The new chemical 
entity (NCE) generated under OSDD will be 
undertaken for clinical trials using a consortium 
of Pharma industries that will be given 
manufacturing rights. The IPR would be held by 
CSIR which proposes to make the NCE 
generated by OSDD as ‘generic’ by sharing it 
with multiple pharmas. This may stimulate some 
healthy competition, but will help avoid or 
discourage sole proprietary motivation and also 
help to bring the cost of a potential drug 
molecule as low.  
FUTURE DIRECTIONS: PERSONALIZED 
MEDICINES   
The availability of human genome sequence has 
heralded a new era of predictive medicine 
yielding an interesting aspect of future drug 
development and biomarker discovery. Complex 
disorders like epilepsy, schizophrenia, diabetes, 
cardiovascular disorder are some of the major 
public health problems even in India. It requires 
long term medication and leads to an expensive 
treatment through conventional methods. Hence, 
availability and affordability of drugs to combat 
such complex disorders is a key factor. 
Pharmacogenomics, which has the potential to 
reveal the genetic basis of adverse drug reaction 
and modulating therapies to specific genetic 
profiles of patients, is expected to play a key 
role in clinical medicine in the coming years. 
The choice of antieplileptic drugs in patients, for 
instance, is based mainly on efficacy and safety. 
However, a section of Indian sub-population 
tolerates much smaller doses of antiepileptic 
drugs as compared to other populations with 
different genetic profiles. One of the aims of 
pharmacogenomics is to implement the concept 
of ‘personalized medicines’ by fine tuning of 
such drug dose adjustments to minimize side 
effects and improve absorption, transport and 
metabolism of these drugs in a population 
specific manner.  This also raises the potential of 
making affordable drugs in near future by 
reviving withdrawn drugs for use by specific 
sub-populations only thereby also minimizing 
their side effects. In order to keep the low cost or 
withdrawn drugs in the market, identification 
and development of drug response biomarkers 
would also be of immense therapeutic potential. 
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The biomarkers identified in this respect would 
not only help in diagnosis of disease conditions 
and predict efficacy of different drugs but also in 
prediction of risk of disease in some 
populations. 
In an effort to generate a map of genetic 
structure of Indian population which will help 
compare the same with other populations, 
mapping of single nucleotide polymorphisms 
(SNPs) in 55 diverse populations of India was 
carried out (Indian Genome Variation 
Consortium, 2008). This is a 
significant achievement wherein comprehensive 
analysis of the Indian population with respect to 
disease predisposition and drug response genes 
has been carried out. Details of this study are 
available in the form of a database, IGVdb 
(http://www.igvdb.res.in/). This database would 
be used to provide basis for epidemiological data 
to differentiate patients on the basis of their 
response to a drug. This would be of immense 
value in pharmacogenomics or predictive 
medicine & drug response in the country. A 
study conducted on Indian population to monitor 
the response of drug salbutamol revealed a 
significant genotypic association of a non 
synonymous SNP (Kukreti et al., 2005). 
Populations having AA genotype at nucleotide 
position 46 of beta adrenergic receptor gene 
were poor responders of the drug while the 
population with genotypic frequency GG were 
good responders. In another recent study, a 
functional polymorphism at codon 158 
(Val/Met) (due to G/A transition) in catechol-O-
methyltransferase (COMT) gene is found to be 
very important for the metabolism of 
catecholamines and catechol estrogens. Val/Val 
genotype was found to have a three–four fold 
higher activity of the COMT enzyme than 
Met/Met genotype. In clinical based studies 
there are evidences that the Val158Met 
polymorphism could be related to response to 
typical and atypical antipsychotics (Illi et al., 
2007). In a study conducted on south Indian 
population, a plausible link between response to 
risperidone and specific polymorphisms located 
within the COMT gene (Gupta et al., 2009) were 
found. Furthermore, data for the Indian 
population for COMT SNP at codon 158 
(Val/Met) showed variable allelic frequencies 
(Kukreti et al., personal communication) among 
the studied 24 populations (Figure 1). This data 
may provide a framework for designing future 
epidemiological studies to identify 
subpopulations with differential response to a 
given drug. Such studies would also open a new 
era of preventive medicine away from curative 
medicine. 
CONCLUSIONS 
India’s R&D strengths in the last few decades 
have been in the fields of organic synthesis, 
purification, extraction and structure elucidation 
of small molecules. This has powered India to be 
a world leader in the production of generics and 
a provider of affordable drugs the world over. 
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Indian national R&D institutions and pharma 
companies have acclaimed huge successes by 
doing reverse engineering and at the same time 
have acquired skills and confidence to engage 
into high-end research and technology 
development.  Several programs have been 
developed to bring industry and national R&D 
laboratories at a common platform to 
complement each other and implement this 
newly found confidence into the drug discovery 
and development process. Despite initial 
successes in new drug development, generics 
will continue to be one of the major strengths of 
Indian pharma industry in the coming years. The 
recent economic recession and stringent 
regulatory action for approval of new drugs are 
among some of the factors that will push pharma 
industries towards generics products.  Moreover, 
an estimated $62 billion worth of drugs are 
expected to be out of patent during 2006-2010 
including some of the ‘blockbuster drugs’ such 
as Merck’s simvastatin, GSK’s fluticasone, 
Pfizer’s cetirizine and GSK’s carvedilol etc 
(https://www.prescriptionsolutions.com/c/rxnew
s/rxnews.asp). This opens up the market for 
important drugs that can be made available as 
generics and the Indian pharma industry would 
help in bringing down the cost by taking up the 
production of these blockbuster drugs.  
India’s foray into drug development and patent 
reforms in the 1970s helped achieve affordable 
healthcare to its people. Under the new IPR 
regime since 2005, following the patent 
amendment as per WTO agreement, India has 
now included product patents along with process 
patents.  The new patents regime also allows for 
patenting of herbal preparations.  In order to 
exploit traditional medicinal knowledge for cure 
of various diseases, Department of Ayurveda, 
Yoga & Naturopathy, Unani, Siddha and 
Homoeopathy-(AYUSH) in collaboration with 
CSIR is creating a Traditional Knowledge 
library.  This would not only help in 
(re)exploring traditional medicines as 
pharmacophores but also help in preventing 
patenting of prior knowledge by MNCs.  In 
addition, India has reinvigorated its research 
programs in the field of herbal medicines and 
formulations to develop products with IPR 
potentials at affordable costs. Several new 
avenues of drug development are also being 
explored.  Increased attention is being given to 
new and upcoming fields to develop generic 
versions of ‘biotherapeutics’ a relatively new 
class of medicines based on proteins/ 
biomolecules made by living cells. Many 
genetically engineered protein molecules are 
increasingly being used to treat diabetes, 
arthritis, cancer, and other diseases. A field 
emerging strongly as an interface of biology and 
engineering, ‘synthetic biology’ aims at design 
of new and natural biological systems to 
synthesize small molecules or their precursors in 
designer biological systems for high efficiency 
and accuracy. Several groups in India have 
begun to explore synthetic biology as an 
important tool to manufacture cost-effective 
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drugs. Combined with the visionary and 
revolutionary projects such as Indian Genome 
Variation and Open Source Drug discovery, 
India is making its presence felt in the global 
scientific map.  While the former aims to 
implement personalized medicines for various 
Indian populations, the latter addresses a menace 
affecting a sizeable portion of its population. 
The national laboratories and academic 
institutions in the country will have to come 
forward to take new and more aggressive 
research initiatives and play a major role to 
bring in the next revolution in the Indian 
pharmaceutical sector to ensure affordable 
healthcare is maintained as a right of all.  
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Table 1. Some leading CROs in India and their major activities. More than 40 CROs are 
approved by DSIR. Complete list is available at DSIR Annual Report, 2007-08.  
Name of Contract Research 
Organization  
Services provided  
Alembic Research Center  The services provided are in the domains of Chemistry, Formulations, Pre-clinical Bioequivalence / Bioanalytical studies 
Aurigene  Offers services in protein sciences, structure based drug design, medicinal chemistry and natural product screening and synthesis  
Bharat Biotech  Manufacturing capabilities in vaccines and biotherapeutics  
Chembiotek Research 
International  
Offers services in medicinal chemistry, chemical process 
development, custom synthesis and analytical chemistry  along with 
assay development, cell and molecular biology methods, in vivo 
pharmacology and computational biology 
Clinigene  Offers services in Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors  
Discovery Partners 
International  
Provides services in areas such as target characterization, library 
design and synthesis, high throughput and high content screening, 
lead generation and optimization, gene expression and protein 
crystallization 
GVK Biosciences  Services in informatics, medicinal chemistry and clinical R&D  
Jubilant 
Jubilant and its subsidiaries (Jubilant Organosys, Jubilant Biosys, 
Jubilant Chemsys, Jubilant Clinsys) provide a complete range of 
manufacturing of small molecule, clinical trials and management 
services 
Premas Biotech  
Offers life science research solutions (Cloning, Expression, Protein 
Purification, Biochemical & Cell Based Assays, Reporter Gene 
Assays, Characterization Studies) along with Protein Production & 
Manufacturing Services  
Reliance Clinical Research 
Services  
Provides preclinical services, Phase I Clinical Trials, Phase II-IV 
clinical trial management, monitoring and training  
Shantha Biotech  
Services in the fields of gene cloning, monoclonal and polyclonal 
antibody development, fermentation, recombinant protein expression 
and purification, optimization of fermentation processes  
Siro ClinPharma  Services in different phases of clinical trials and in all key areas of the drug development process.  
Strand Solutions  Offers value-added technology services in the field of bioinformatics, cheminformatics, data management and automation  
Syngene  Offers services in synthetic chemistry and molecular biology for early stage drug discovery and development  
Veeda  Full service global CRO specializing in the early clinical development of drugs.  
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  Legends to the Figure 
Figure 1: Gradient map showing distribution of allelic frequencies associated with COMT 
(rs4680) (G/A) in Indian populations.  The color gradient (light to dark) depicts the range of 
observed frequency from minimum to maximum.  
 
 
